Temgo 200 mcg
Contraindications: Hypersensitivity to buprenorphine. Transdermal patch Buccal film: (Additional) Significant respiratory depression severe asthma in an unmonitored setting or in absence of resuscitative equipment known or suspected GI obstruction including paralytic ileus.Pregnancy/Lactation: Crosses placenta. Distributed in breast milk. Breastfeeding not recommended. Neonatal withdrawal noted in infant if mother was treated with buprenorphine during pregnancy with onset of withdrawal symptoms generally noted on day 1 manifested as hypertonia tremor agitation myoclonus. Apnea bradycardia seizures occur rarely. Children: Safety and efficacy of Injectionection form not esTabletlished in those 2?12 yrs. Safety and efficacy of Tabletlet fixed-combination form not esTabletlished in pts 16 yrs or younger. Elderly: Age-related hepatic impairment may require dosage adjustment.
Sublingual Tabletlet: Treatment of opioid dependence. Implant: Maintenance
treatment of opioid dependence in pts who achieved/sustained prolonged clinical
sTabletility on low to moderate doses of a transmucosal buprenorphine product for
3 months or longer with no need for supplemental dosing or adjustments.
Injectionection: Relief of moderate to severe pain. Transdermal Buccal film:
Moderate to severe chronic pain requiring continuous around-the-clock opioid
analgesic for extended period. OFF-LABEL: Injectionection: Heroin/opioid
withdrawal in hospitalized pts.
impairment elderly debilitated pediatric pts head Injectionury/increased intracranial
pressure pts at risk for respiratory depression hyperthyroidism myxedema
adrenal cortical insufficiency (e.g. Addison?s disease) urethral stricture CNS
depression morbid obesity toxic psychosis prostatic hypertrophy delirium
tremens kyphoscoliosis biliary tract dysfunction acute pancreatitis acute
abdominal conditions acute alcoholism pts with prolonged QT syndrome
concurrent use of antiarrhythmics hypovolemia cardiovascular disease ileus
bowel obstruction hx of seizure disorder.